Introducting the world's first drug-eluting SFA stent

Results:

Proven to reduce
reinterventions by 50%

The Zilver PTX (paclitaxel) drug-eluting stent has been proven to reduce reintervention rates in the SFA (superficial femoral artery) by 50% when compared to other leading stents.¹ Combine our next-generation durability with our 100% polymer-free paclitaxel drug delivery, and you have a tremendously powerful weapon against peripheral disease. Learn More »

1. Dake M. Interim analysis of two-year results for the Zilver PTX drug-eluting peripheral stent. Presented at: 2009 Vascular Annual Meeting; June 11-14, 2009; Denver, CO.

Video:

Key Advantages:

SUPERIOR SFA RESULTS

The Zilver PTX is proven in the most rigorous SFA studies ever conducted. More »

POLYMER-FREE PACLITAXEL DELIVERY

The Zilver PTX blocks cell proliferation that can lead to restenosis, while eliminating the unnecessary polymer that may cause long-term problems. More »

NEXT-GENERATION DURABLE DESIGN

Zilver PTX nearly eliminates the risk of stent fractures. More »

News:

CIRSE 2009, Lisbon Portugal

Zilver PTX Used at 31 Sites
Zilver PTX continues to receive positive physician input after being implanted across five countries (Italy, France, Germany, Spain, UK), which included 31 clinical sites and 45 patients. More »

Instructions for Use:

Please refer to the Zilver PTX IFU for indications,
contraindications, warnings, precautions and
potential adverse events.

Advancing Leg Therapies

Click here to stay informed.
Sign up for our e-mail newsletter.